Navigation Links
Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
Date:4/4/2012

interferon-free, all-oral regimens for previously treated and treatment-naive patients with HCV," said Jay Luly, Ph.D., President and CEO of Enanta.  "Enanta's involvement in five distinct HCV drug classes provides multiple avenues to pursue our goal of bringing to patients innovative therapies that are safer and more effective than current treatments."

Oral Presentations

Oral Presentation, Eric Lawitz et al.; Thursday, April 19, 16:00-18:00 CET / 10:00 am - 12:00 pm EDT.
A 12-week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Naive HCV IL28B-CC Genotype-1-Infected Subjects

  • The objectives of the 12-week, phase 2 study were to assess the safety, tolerability, pharmacokinetics, and antiviral activity of ABT-450/r 150/100 mg QD and ABT-072 400 mg QD + ribavirin administered for 12 weeks.
  • The study was conducted in 11 treatment naive adults from multiple ethnic backgrounds with non-cirrhotic HCV GT1 (8 GT 1a, 3 GT 1b). Ribavirin 1000-1200 mg/day was weight-based and dosed twice daily.
  • The primary endpoint was percentage of patients with HCV RNA <25 IU/ml from week 4 through 12. Other trial endpoints include early virologic response, RVR and SVR through 24 weeks.
  • 100 percent of patients maintained HCV RNA levels <25 IU/mL from weeks 4 through 12 of treatment, and all had undetectable HCV RNA from week 5 to the end of treatment.
  • 91 percent of patients achieved SVR24,
  • In the trial, the most common adverse events reported were headache, fatigue, nausea and dry skin. There were no premature discontinuations.

Late-Breaking Oral Presentation, Fred Poordad, et al.; Saturday, April 21, 15:30-17:
'/>"/>

SOURCE Enanta Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
2. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
3. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
4. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
5. Enanta Enters Into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
(Date:12/15/2014)... Washington State are not the only ... Oregon , Alaska , and ... 2014 elections. Photo - http://photos.prnewswire.com/prnh/20141212/164152 ... The benefits of legalizing cannabis are manifold. There are the ... revenue for state and local governments, in addition to reduced ...
(Date:12/15/2014)... SAN MARCOS, Texas , Dec. 15, 2014 /PRNewswire/ ... quantum dot manufacturer Quantum Materials Corp (OTCQB:QTMM), ... Rice Center for Quantum Materials (RCQM) on December 16th, ... the exploration of exotic nanomaterials in attracting top faculty ... to Rice to collaborate on research. ...
Breaking Medicine Technology:Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3
... Agennix Incorporated today announced,the publication of final ... alfa in patients who had failed previous treatment ... from the study,which were reported in the July ... 1), demonstrate that talactoferrin is active in RCC, ...
... Evaluate Preventive Treatment of ... Vulnerable Plaques, ROTTERDAM, Netherlands and DOYLESTOWN, Pa., June ... W. Serruys,successfully placed a vProtect(TM) Luminal Shield in the ... at Erasmus Medical,Center in Rotterdam. This case marks the ...
Cached Medicine Technology:Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 2Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 3Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 4Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 5Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 2Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... accurate method of assessing people at risk from cardiovascular disease ... those at risk among black and minority ethnic groups. ... most at risk of developing CVD for the first time, ... and other clinical conditions such as family history of heart ...
... 24 The Rehabilitation Institute,of Chicago and MediCom ... on Pain July 18th and 19th. The meeting ... of Northwestern University in Chicago., This year, ... Opioid,Management." The scientific agenda will focus on the ...
... Food Snacks Contain Ingredients Medically Proven to Reduce ... Impact of Diagnosed ... In response to increasing,demand for convenient, tasty, satisfying foods ... WatchDog Nutrition(TM) today announced,availability of its snack bars in ...
... BETHLEHEM, Pa., June 24 At this year,s ... Inc. and its MIKE AND,IKE(R) Candy Brand presented ... the first in a multi-year commitment to this ... MIKE AND IKE(R) Lemonade Blends(TM) kicks off Just ...
... June 24 Go Healthy, Inc. (Pink,Sheets: GOHE) announced ... AIM Marketing, based in Myakka, Florida. Under the terms ... number of marketing and,sales related services designed to bring ... clients. Some specifics outlined in the agreement,are as follows:, ...
... June 24 /PRNewswire-FirstCall/ - Beeston Enterprises Ltd.,("Beeston" or ... on its Bluff Lake property that it holds ... "CDO"). The property is,located on the northern border ... continues to delineate significant alkalic copper-gold deposits., ...
Cached Medicine News:Health News:New cardiovascular score developed to improve heart attack and stroke detection 2Health News:3rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide, Inc. 2Health News:Heart Disease and Diabetes Finally Meet Their Match With Delicious New Snack Bars From WatchDog Nutrition(TM) 2Health News:MIKE AND IKE(R) Lemonade Blends(TM) Presents $100,000 to Alex's Lemonade Stand Foundation 2Health News:Go Healthy Signs Marketing Contract with AIM Marketing 2Health News:Beeston completes drilling on Bluff Lake property, 100 Mile House 2
A straight suture punch with 2.5 mm needle and 2/0 to #1 monofilament suture....
Leg holder for arthroscopy....
... High-Performance Pump in Arthroscopy. Ease of use ... that make the 10k Fluid System unique. ... for Arthroscopy, maintains intra-articular pressure, while providing ... Fluid System, when used for Laparoscopy, provides ...
The Sony DSR20-MD Grade Digital Video Player/Recorder represents a giant leap in digital technology. , ,This equipment is intended to be used by physicians who teach or present medical techniques...
Medicine Products: